Clavis Pharma's MD Olav Hellebø is leaving the company. This the result of ongoing downscaling in the company following the failed test results for a cancer medication that has been under development.
1st Jan change | Capi. | |
---|---|---|
+25.40% | 45.54B | |
+34.52% | 24.51B | |
+27.12% | 16.48B | |
+21.19% | 14.66B | |
+71.91% | 14.3B | |
-0.05% | 6.79B | |
-11.84% | 6.73B | |
+18.15% | 5.87B | |
-8.87% | 5.73B |